MRKR - התחייבויות לטווח ארוך של החברה Marker Therapeutics

Marker Therapeutics (MRKR) delegates large-scale trials and the transportation of biomaterials to external partners. This market valuation on GURU.Markets captures the 0.00 metric, while the business scales its immunotherapy developments through grant support. The innovative MultiTAA system enables effective targeting of multiple tumor antigens, creating a safe method for combating blood diseases.

This indicator aggregates total liabilities with a maturity of more than one year, measuring the financial leverage and stability of the company's capital structure. By analyzing the long-term liabilities chart of the issuer, an investor assesses the ability of Marker Therapeutics (MRKR) to fund the MultiTAA platform, where fixed R&D costs must be balanced by debt to ensure the future scaling of therapy and the conversion of a monopoly into profit.